Background/Objectives: Several studies havereported that non-alcoholic fatty liver disease (NAFLD) is more frequent in patients with psoriasis, but few have reviewed the presence of liver fibrosis in those patients. Conclusions:Elastography may be a useful tool along with ultrasound to evaluate liver disease in patients with psoriasis.

In recent years, there has been an increase in publications that relate psoriasis to non-alcoholic fatty liver disease (NAFLD), with the consequent risk of progression to liver fibrosis, cirrhosis and hepatocarcinoma. 1 It has been speculated that both entities share common pathophysiological mechanisms. Among them, the overproduction of proinflammatory cytokines such as interleukin-17 could contribute to the development of psoriasis skin plaques and the progression of liver disease, so its blockage could be beneficial for both entities. 2 In this study we investigated the possible antifibrotic effect of secukinumab in psoriasis patients treated for at least 2 years. We use secukinumab because it has shown favorable effects on metabolic and liver parameters. 3 Liver elasticity was assessed by Transient Elastography (TE), using Fibroscan. Results reliability was defined by at least 10 valid measurements, success rate ≥60%, and interquartile range to median ratio ≤30%.A total of 10 psoriasis patients treated with secukinumab were collected. The clinical-epidemiological characteristics are summarized in Table 1. Only 2 of the 10 patients started lipid-lowering drugs after first Fibroscan performing. The Fibroscan value improved in all

No abstract

No abstract

No abstract